Indivior Pharmaceuticals, Inc. (INDV)
Summary
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.
5 Top-Ranked Efficient Stocks Beating Industry Peers on Key Metrics
INDV, RNW, LCUT, NTCT and TNK passed a screen for efficiency, outperforming industry peers on inventory, receivables, assets and margins.
4 Must-Buy Efficient Stocks to Enrich Your Portfolio in 2025
INDV, PRLB, LVS and OII top Zacks' efficiency screen with strong margins and solid earnings surprises.
Indivior Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 183 | $6,565.79 | $7,087.59 | $521.8 | 7.95% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 577,477 | $20.29M | $22.42M | $2.13M | 10.48% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 42 | $1,280.16 | $1,614.06 | $333.9 | 26.08% |
| MA mason adams PVG ASSET MANAGEMENT Corp. | 5,365 | $220,126 | $214,653.64 | -$5,472.36 | -2.49% |
| LN Louis Navellier NAVELLIER & ASSOCIATES Inc. | 173,860 | $6.35M | $6.96M | $607,877.34 | 9.58% |
Indivior Pharmaceuticals, Inc. (INDV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Indivior Pharmaceuticals, Inc. ever had a stock split?
Indivior Pharmaceuticals, Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Joseph J. Ciaffoni CEO | NASDAQ (NGS) Exchange | 45579U109 CUSIP |
| US Country | 833 Employees | - Last Dividend | - Last Split | 29 Dec 2014 IPO Date |
Overview
Indivior PLC operates within the pharmaceutical industry, focusing on the development, manufacture, and sale of buprenorphine-based prescription drugs aimed at treating opioid dependence and related disorders. With a global presence, including significant operations in the United States, the United Kingdom, and other international markets, the company spearheads initiatives to address substance use disorders, serious mental illnesses, and opioid overdose. Established in 2014, Indivior's mission is underscored by its commitment to offer innovative therapeutic solutions, catering to a range of needs within the ambit of opioid use disorder (OUD) and beyond. Headquartered in North Chesterfield, Virginia, Indivior leverages its scientific and operational expertise to advance a pipeline of products and services designed to improve patient outcomes in the areas of substance abuse and mental health.
Products and Services
- SUBLOCADE and SUBUTEX PRO: Buprenorphine extended-release monthly injections, these are core marketed products designed for the sustained management of opioid use disorder. SUBLOCADE is administered as an injectable while SUBUTEX PRO offers a similar long-term relief in managing addiction symptoms.
- SUBOXONE: Available both as a sublingual film and a tablet, SUBOXONE combines buprenorphine and naloxone. This formulation is aimed at reducing opioid cravings and withdrawal symptoms while blocking the high effects of opioid use, thus facilitating recovery and maintenance therapy for those battling opioid addiction.
- SUBUTEX: This is a buprenorphine sublingual tablet formulated to suppress symptoms of opioid withdrawal. By providing a buprenorphine-only product, SUBUTEX is another avenue for patients seeking opioid dependency treatment with a focus on reducing the potential for misuse.
- OPVEE Nasal Spray: A naloxone-based nasal spray, OPVEE is crafted for the rapid reversal of opioid overdose. Its intranasal delivery system is designed for easy administration, making it an essential tool in emergency situations involving opioid intoxication.
- PERSERIS: A long-acting injectable suspension for the treatment of schizophrenia in adults, PERSERIS employs extended-release technology to provide patients with a consistent delivery of medication, aimed at improving the management of schizophrenia symptoms over time.
- Research and Development: Indivior is actively engaged in developing a diverse pipeline of treatments for substance use disorders and mental illnesses. Notably, INDV-2000, a promising orexin-1 receptor antagonist, is under clinical trials for opioid use disorder. Collaboration with ADDEX Therapeutics has resulted in INDV-1000, targeting alcohol use disorder, while partnership with Alar Pharmaceuticals Inc. focuses on INDV-6001, a long-acting injectable for OUD. The company's venture into digital therapeutics is highlighted by its development of CT-102 with Click Therapeutics for OUD treatment. Additionally, INDV-5004, aimed at treating acute cannabinoid overdose, and AEF0117, developed in partnership with Aelis Farma for cannabis use disorder, further exemplify Indivior's commitment to addressing a broad spectrum of substance-related disorders.
